FindTrial
Sign In

Mechanism study on the regulation of Rap1b/VEGFR2 signaling axis by exosome hsa_circ_0001240 to activate angiogenesis and promote the occurrence and development of esophageal squamous cell carcinoma

Mechanism study on the regulation of Rap1b/VEGFR2 signaling axis by exosome hsa_circ_0001240 to activate angiogenesis and promote the occurrence and development of esophageal squamous cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095801
Enrollment
Unknown
Registered
2025-01-13
Start date
2025-01-13
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

Group of esophageal squamous cell carcinoma:None

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.ECOG<=2;NRS2002<=1; 2.Esophageal squamous cell carcinoma patients without a history of radiotherapy or chemotherapy; 3.Age limit: 25-75 years old, participants can decide the details of the trial on their own; No gender restrictions.

Exclusion criteria

Exclusion criteria: 1.Hematological diseases such as hemorrhagic purpura or coagulation dysfunction, or inability to collect blood samples or undergo surgical treatment due to various reasons; 2.Any history of malignant tumors; 3.Age75 years old.

Design outcomes

Primary

MeasureTime frame
Circular RNA and related proteins;—

Countries

China

Contacts

Public ContactLiji Wang

Ningbo Medical Centre Lihuili Hospital

dlwangljnb@163.com+86 574 55836258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026